Huasun plans to publicly list and transfer 51% equity of Tibet Kangyu
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, Huasun announced that the company plans to publicly transfer 51% of the equity of its controlling subsidiary Tibet Kangyu Pharmaceutical Co., Ltd. (referred to as "Tibet Kangyu") at a listing price of 63.7806 million yuan. The equity transfer will be conducted through public listing at the Southwest United Property Rights Exchange, and the buyer has not yet been determined
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments